BioXcel rises on FDA's 'fast track' tag for prostate cancer therapy

BioXcel Therapeutics

12/02/2024 13:49

** Shares of BioXcel Therapeutics  BTAI.O  rise 10% to $2.32
premarket  
    ** Co says the U.S. Food and Drug Administration (FDA) has
granted "fast track" status to its experimental combination
therapy being developed to treat a type of prostate cancer 
    ** The therapy, BXCL701, in combination with an
immunotherapy is being tested to treat patients with metastatic
small cell neuroendocrine prostate cancer (SCNC) which has
progressed after chemotherapy -BTAI     
    ** Says plans to discuss registration path for BXCL701 at an
upcoming meeting with the FDA -BTAI
    ** FDA's "fast track" status facilitates the development and
expedites the review of medicines to treat serious conditions
    ** Up to last close, stock down ~94% in the last 12 months 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))